摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-二氯喹唑啉-4(3H)-酮 | 6958-39-0

中文名称
6,7-二氯喹唑啉-4(3H)-酮
中文别名
——
英文名称
6,7-dichloroquinazolin-4(3H)-one
英文别名
6,7-Dichloroquinazolin-4(3H)-one;6,7-dichloro-3H-quinazolin-4-one
6,7-二氯喹唑啉-4(3H)-酮化学式
CAS
6958-39-0
化学式
C8H4Cl2N2O
mdl
——
分子量
215.039
InChiKey
UESAHLRLKCVJGK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319
  • 储存条件:
    室温下应存放在干燥密封的环境中。

SDS

SDS:d51d24629b4dbddfbb2fb71a578f04ae
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6,7-二氯喹唑啉-4(3H)-酮copper(l) iodide 、 sodium azide 、 potassium carbonate三苯基膦 作用下, 以 四氢呋喃二甲基亚砜N,N-二甲基甲酰胺 为溶剂, 反应 3.5h, 生成
    参考文献:
    名称:
    一类喹唑啉酮-苏氨酸杂化物作为抗菌ThrRS抑制剂的结构导向优化及机理研究
    摘要:
    氨酰基-tRNA合成酶(aaRSs)由于其在蛋白质翻译中的重要作用而成为一类有吸引力的抗菌药物靶标。虽然大多数传统的aaRS抑制剂都靶向底物氨基酸和/或ATP的结合口袋,但我们最近开发了一类新型tRNA-氨基酸双位抑制剂,包括抑制剂3((2 S,3 R)-2-amino- N -((E)-4-(6,7-dichloro-4-oxoquinazolin-3(4 H)-yl)but-2-en-1-yl)-3-hydroxybutanamide)反对苏氨酸tRNA合成酶(ThrRS) 。在此,通过肠沙门氏菌ThrRS(Se)的晶体结构分析了这些抑制剂的结合模式和构效关系(SARs)。ThrRS)与其中三个复杂。基于共晶体结构,设计并合成了十二种喹唑啉酮-苏氨酸杂化物,并评估了它们的亲和力,酶抑制活性和细胞效能。最好的衍生物8g的K d值为0.40μM,对Se ThrRS的IC 50值为0.50μ
    DOI:
    10.1016/j.ejmech.2020.112848
  • 作为产物:
    参考文献:
    名称:
    AN ANTIMALARIAL ALKALOID FROM HYDRANGEA. XV. SYNTHESIS OF 5-, 6-, 7-, AND 8-DERIVATIVES WITH TWO IDENTICAL SUBSTITUENTS
    摘要:
    DOI:
    10.1021/jo01135a015
点击查看最新优质反应信息

文献信息

  • Quinazolin-4(3H)-one derivatives as anticoccidial agents
    申请人:Pfizer Inc.
    公开号:US04762838A1
    公开(公告)日:1988-08-09
    Variously substituted trans-3-[3-(3-hydroxypiperid-2-yl)-2-oxopropyl]quinazolin-4-(3H)-ones, a method of controlling or preventing coccidiosis in poultry therewith, intermediates therefor, and a process for the preparation of certain intermediates therefor.
    各种取代的trans-3-[3-(3-羟基哌啶-2-基)-2-氧代丙基]喹唑啉-4-(3H)-酮,用于控制或预防家禽球虫病的方法,其中间体以及某些中间体的制备方法。
  • Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase
    作者:Bao Cheng、Zhengjun Cai、Ziqing Luo、Siting Luo、Zhiteng Luo、Yanfang Cheng、Ying Yu、Junsong Guo、Yingchen Ju、Qiong Gu、Jun Xu、Xianxing Jiang、Geng Li、Huihao Zhou
    DOI:10.1021/acs.jmedchem.2c01496
    日期:2022.12.8
    Aminoacyl-tRNA synthetases (aaRSs) are promising antimicrobial targets due to their essential roles in protein translation, and expanding their inhibitory mechanisms will provide new opportunities for drug discovery. We report here that halofuginone (HF), an herb-derived medicine, moderately inhibits prolyl-tRNA synthetases (ProRSs) from various pathogenic bacteria. A cocrystal structure of Staphylococcus
    氨酰-tRNA 合成酶 (aaRS) 是很有前途的抗菌靶点,因为它们在蛋白质翻译中起着重要作用,扩展它们的抑制机制将为药物发现提供新的机会。我们在此报告,一种草药衍生药物 halofuginone (HF) 适度抑制来自各种病原菌的脯氨酰-tRNA 合成酶 (ProRSs)。确定了金黄色葡萄球菌ProRS ( Sa ProRS) 与 HF 和 ATP 类似物的共晶结构,这指导了新 HF 类似物的设计。化合物3在 IC 50 = 0.18 μM 和K d = 30.3 nM 时有效抑制Sa ProRS,并在体外显示出抗菌活性,MIC 为 1–4 μg/mL. 细菌对3的耐药性仅以类似于或慢于临床使用的体外抗生素的速度产生。我们的研究表明,HF 的支架和 ATP 辅助抑制机制可应用于细菌 ProRS,并且还为使用细菌 ProRS 作为抗菌靶点提供了化学验证。
  • Design and Evaluation of New Quinazolin-4(3<i>H</i>)-one Derived PqsR Antagonists as Quorum Sensing Quenchers in <i>Pseudomonas aeruginosa</i>
    作者:Fadi Soukarieh、Alaa Mashabi、William Richardson、Eduard Vico Oton、Manuel Romero、Shaun N. Roberston、Scott Grossman、Tomas Sou、Ruiling Liu、Nigel Halliday、Irena Kukavica-Ibrulj、Roger C. Levesque、Christel A. S. Bergstrom、Barrie Kellam、Jonas Emsley、Stephan Heeb、Paul Williams、Michael J. Stocks、Miguel Cámara
    DOI:10.1021/acsinfecdis.1c00175
    日期:2021.9.10
  • Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping
    作者:Junsong Guo、Bingyi Chen、Ying Yu、Bao Cheng、Yanfang Cheng、Yingchen Ju、Qiong Gu、Jun Xu、Huihao Zhou
    DOI:10.1016/j.ejmech.2019.111941
    日期:2020.2
    Threonyl-tRNA synthetase (ThrRS) is a key member of the aminoacyl-tRNA synthetase (aaRS) family that plays essential roles in protein biosynthesis, and ThrRS inhibitors have potential in the therapy of multiple diseases, such as microbial infections and cancers. Based on a unique tRNA-amino acid dual-site inhibitory mechanism identified recently with the herb-derived prolyl-tRNA synthetase (ProRS) inhibitor halofuginone (HF), a series of compounds have been designed and synthesized by employing a fragment-based target hopping approach to simultaneously target the tRNA(Thr) and L-threonine binding pockets of ThrRS. Among them, compound 30d showed an IC50 value of 1.4 mu M against Salmonella enterica ThrRS (SeThrRS) and MIC values of 16-32 mu M/mL against the tested bacterial strains. The cocrystal structure of SeThrRS in complex with 30d was determined at high resolution, revealing that 30d simultaneously occupies both binding pockets for the nucleotide A76 of tRNA(Thr) and L-threonine in an ATP-independent manner, a novel mechanism compared to all other reported ThrRS inhibitors. Our study provides a new class of ThrRS inhibitors, and more importantly, it presents the first experimental evidence that the tRNA-amino acid dual-site inhibitory mechanism could apply to other aaRSs beyond ProRS, thus providing great opportunities for designing new mechanistic inhibitors for aaRS-based therapeutics. (C) 2019 Elsevier Masson SAS. All rights reserved.
  • ROUBINEK, F.;VAVRINA, J.;BUDESINSKY, Z., COLLECT. CZECH. CHEM. COMMUN., 1982, 47, N 2, 630-635
    作者:ROUBINEK, F.、VAVRINA, J.、BUDESINSKY, Z.
    DOI:——
    日期:——
查看更多